Phase I study of PD-0332991 for pediatric patiens with retinoblastoma protein (RB)-positive recurrent or refractory central nervous system (CNS) tumors.

Administered By

Awarded By

Contributors

Start/End

  • September 1, 2014 - December 31, 2026